Chlordiazepoxide and Metabolites
Use
Quantitative measurement of the benzodiazepine drug chlordiazepoxide and its metabolites (norchlordiazepoxide and nordiazepam) to monitor therapeutic levels, detect compliance, or assess potential toxicity in patients receiving chlordiazepoxide therapy.
Special Instructions
Not provided.
Limitations
Room‐temperature specimens are unacceptable; specimens collected in SST tubes are rejected. Hemolytic, lipemic, or otherwise compromised specimens may affect accuracy. Analytical performance is validated under CLIA but the assay is not FDA cleared/approved.
Methodology
Mass Spectrometry
Biomarkers
Chlordiazepoxide
AnalyteNorchlordiazepoxide
AnalyteNordiazepam
Analyte
Result Turnaround Time
6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
no additive (red‑top) tube, transferred to a plastic screw‑cap vial
Collection Instructions
Use red‑top tube; SST not acceptable
Patient Preparation
Collect at trough concentration (just before next dose)
Storage Instructions
Refrigerate within 1 hour; ship on cold pack
Causes for Rejection
Specimen in SST tube; room temperature; hemolysis or lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 5 days |
| Frozen | 14 days |
Other tests from different labs that may be relevant